Pfizer hands PR for migraine drug launch to EMC

Pharmaceutical giant Pfizer has appointed EMC Euro PR to handle PR for the launch of its new migraine drug, Eletriptan, in Europe and the US.

Pharmaceutical giant Pfizer has appointed EMC Euro PR to handle PR

for the launch of its new migraine drug, Eletriptan, in Europe and the

US.



EMC Euro was appointed after a four-way pitch and will work in

conjunction with its New York affiliate agency, healthcare specialist M

Booth and Associates.



The agency will conduct a media relations campaign from this month into

the year 2000. It will target the European medical profession, with

potential for broader PR activity closer to the launch date in 2000. The

account will be headed by Katie Randerson, associate director at EMC

Euro.



A spokeswoman for the agency said: ’We will be designing and executing

the pre-launch PR campaign. This is an area EMC Euro is increasingly

moving into.’



Pfizer retains Edelman PR Worldwide as its corporate affairs agency and

GPC Market Access for public affairs. Ruder Finn co-ordinates worldwide

consumer and healthcare PR for the company’s impotence drug Viagra.



EMC clients include pharmaceutical company Dendron, vitamins and

minerals manufacturer Wasson International and acupressure wrist bands

producer Sea Bands.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.